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Abstract
Background: Previous studies of the natural history of alpha-1-antitrypsin (AAT) deficiency are mostly based on highly 
selected patients. The aim of this study was to analyse the mortality of PiZZ individuals.
Methods: Data from 1339 adult PiZZ individuals from the Swedish National AAT Deficiency Registry, followed from 
1991 to 2008, were analysed. Forty-three percent of these individuals were identified by respiratory symptoms 
(respiratory cases), 32% by liver diseases and other diseases (non-respiratory cases) and 25% by screening (screened 
cases). Smoking status was divided into two groups: smokers 737 (55%) and 602 (45%) never-smokers.
Results: During the follow-up 315 individuals (24%) died. The standardised mortality rate (SMR) for respiratory cases 
was 4.70 (95% Confidence Interval (CI) 4.10-5.40), 3.0 (95%CI 2.35-3.70) for the non-respiratory cases and 2.30 (95% CI 
1.46-3.46) for the screened cases. The smokers had a higher mortality risk than never-smokers, with a SMR of 4.80 
(95%CI 4.20-5.50) for the smokers and 2.80(95%CI 2.30-3.40) for the never-smokers. The Rate Ratio (RR) was 1.70 (95% CI 
1.35-2.20). Also among the screened cases, the mortality risk for the smokers was significantly higher than in the 
general Swedish population (SMR 3.40 (95% CI 1.98-5.40).
Conclusion: Smokers with severe AAT deficiency, irrespective of mode of identification, have a significantly higher 
mortality risk than the general Swedish population.
Introduction
Severe alpha-1-antitrypsin deficiency (AATD) is a hered-
itary condition characterised by low levels of AAT in
serum and the lungs, a high risk of developing panacinar
emphysema, and an increased risk of liver disease, pri-
marily in early childhood and late adulthood [1-6]. Ciga-
rette smoking is strongly associated with early
development of emphysema in PiZZ individuals [2].
Previous studies of the natural history of severe AATD
have indicated that it is a severe disorder leading to a con-
siderably reduced life expectancy, and that emphysema is
the most common cause of death [2]. However, our
recently published study showed that PiZZ individuals,
who have never smoked and have been identified by
screening, do not have an increased mortality risk com-
pared with the general Swedish population [7]. We also
found that emphysema and liver diseases were the most
common causes of death. Smokers were not included in
the analysis.
The aims of this study were to analyse the mortality of
PiZZ individuals, with respect to smoking habits and the
mode of identification, to analyse the predictors of mor-
tality, and further, to analyse the most common causes of
death.
Subjects and Methods
Study population and data collection
The patients were selected from the Swedish National
AATD Registry, which was started in 1991 [8]. Eligibility
criteria for inclusion in the registry have been described
previously [7]. Briefly, all PiZZ individuals in Sweden
aged 18 years and over, are invited to participate in the
registry. After inclusion, the patients are followed-up
every 2 years by their attending physician. Smoking hab-
its, symptoms, diagnoses, results of lung function and
liver function tests are reported to the registry via a ques-
tionnaire.
The initial reasons for AAT analysis leading to the diag-
nosis of severe AATD were obtained from the question-
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naire. The patients identified by the presence of
respiratory diseases or symptoms, including repeated
respiratory tract infections, are referred to as "respiratory
cases" (R cases). The patients identified because of other
diseases or symptoms are referred to as "non-respiratory
cases" (NR cases). The NR cases include liver diseases,
renal diseases, joint symptoms, repeated infections other
than respiratory tract infection, high sedimentation rate,
or other signs and symptoms for which plasma protein
analysis has been performed as part of the clinical investi-
gation. The patients identified by family/population
screening are referred to as "screened cases" (S cases).
Details of smoking habits were also obtained from the
questionnaire. Smoking status was based on the subjects'
self-reports and was divided into two groups: smokers
and never-smokers. A smoker was defined as any subject
who had smoked more than one cigarette per day for at
least one year, or more than 20 packs of cigarettes during
his/her life. Smoking history was available for all cases.
Lung function tests were performed at local hospitals
and were requested to be performed in accordance with
European recommendations [9]. Forced expiratory vol-
ume in one second (FEV1) and forced vital capacity (FVC)
were measured. The results of the lung function tests are
expressed as the percentage of predicted values according
to European reference tables [10]. The FEV1/FVC ratios
are expressed as percentages. The results of the first
spirometry at inclusion in the registry were analysed.
Only pre-bronchodilator values were analysed, because a
reversibility test with a bronchodilator was not consis-
tently performed.
The date of death was obtained from the Swedish Reg-
istry of Deaths. Vital status was known for all cases at the
closing point of the study (October 1st, 2008). The dates
of lung and liver transplantations were obtained from the
questionnaire and medical records. For each death, the
medical records from the hospital at which the death
occurred, were reviewed. These records included medical
charts from the terminal hospitalization, last outpatient's
visits (if the patient died at home) and the death certifi-
cate. An autopsy protocol for patients who had under-
gone complete post-mortem examination was obtained
from The Department of Pathology at which the autopsy
was performed. All available records and autopsy proto-
cols were analyzed to determine the main causes of death.
Records and autopsy protocols were also analysed con-
cerning the occurrence of liver disease.
Statistical analysis
Cumulative survival probabilities were estimated using
the Kaplan-Meier method, and differences in survival
were calculated with the log rank test. The period of the
follow-up for the survival calculation was taken from the
date of inclusion in the registry to the date of death, date
of lung/liver transplantation or up to October 1st, 2008
(closing date of the study). Analysis of variance (ANOVA)
was used for group comparisons. The Tukey Honest Sig-
nificant Difference (HSD) test was used for multiple com-
parisons [11]. To compare death rates in the PiZZ
individuals with the general Swedish population, a stan-
dardised mortality ratio (SMR) was calculated as the ratio
of observed to expected deaths. The expected numbers of
deaths were obtained using age-, sex- and date-specific
death rates published in Sweden annually (Statistics Swe-
den) [12]. Confidence intervals for the SMR were com-
puted from the Poisson distribution. The rate ratios for
mortality were calculated as the ratio of the observed
n u m be r  o f  d ea t h s  pe r  pe r so n  y ea r  o f  f o l l o w-u p  t o  t h e
expected death rate. These rate ratios are referred to as
RR. The Cox proportional hazards model was used to
examine the effects of baseline predictors on survival.
The baseline predictors were gender, age at inclusion (in
two categories), pre-bronchodilator FEV1 % of predicted
(divided into four categories according to the GOLD
stages), the presence of respiratory symptoms at inclu-
sion. A p-value of < 0.05 was considered significant.
Results
Study population and lung function
Up to October 2008, a total of 1349 PiZZ individuals were
included in the registry. Ten of them were excluded
because of lung transplantation before being entered in
the registry. The remaining 1339 individuals were
included in the statistical analysis. The demographic
baseline data and the results of lung function tests are
shown in Table 1. The initial reasons for AAT analysis
were: lung disease in 43% (R cases), liver disease and
other diseases or symptoms in 32% (NR cases), and fam-
ily/population screening in 25% of cases (S cases). Among
the NR cases 20% were identified because of liver disease
and 80% because of other diseases or symptoms. The
number of years between the diagnosis and inclusion in
the register ranged from 0.1 to 35 years. At the time of
inclusion, respiratory disease or respiratory symptoms
were reported in 38% of the NR cases and in 30% of the S
cases. The S cases were younger than the R and NR cases
at the time of diagnosis and inclusion. Lung function at
inclusion was significantly lower in the R cases than in
the NR and S cases (p < 0.001), while the difference
between the NR and S cases was not significant. The
mean follow-up time ranged from 0.1 to 17 years with no
significant differences among the three groups.
Fifty five percent of the study population were smokers
and most of them were identified by respiratory symp-
toms (57%). The mean (SD) number of pack years was 15
(13). The smokers were significantly older than never-Tanash et al. Respiratory Research 2010, 11:44
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smokers (p < 0.001). The never-smokers had significantly
higher FEV1 than the smokers (p < 0.001), Table 2.
Of 423 smokers in the R cases, 328 (78%) had emphy-
sema, 61 (14%) chronic bronchitis, 11 (3%) asthma, 5 (1%)
pulmonary fibrosis, 5 (1%) bronchiectasis and 13 (3%)
had repeated respiratory tract infections. Of 151 never-
smokers in the R cases, 71 (47%) had emphysema, 32
(21%) chronic bronchitis, 26 (17%) asthma, 4 (3) pulmo-
nary fibrosis, 6 (4%) bronchiectasis and 12 (8%) repeated
respiratory tract infections.
Survival
Fifty six patients received a lung transplant and two
patients received a liver transplant; their mortality data
are censored at the date of transplant. During the follow-
up time 315 (24%) patients died. The median survival
time for the whole study population since inclusion was
Table 2: Age and results of lung function tests in smokers and never-smokers.
Smokers Never-smokers
Men (%) 50 47
Mean (range) age at inclusion (years) 49 (18-84)* 44 (18-89)
Deaths, no. (%) 208 (28) 107 (19)
Mean (SD) FEV1 (% predicted) 59 (32)* 88 (25)
Mean (SD) FVC (% predicted) 80 (25)* 89 (18)
Mean (SD) FEV1/FVC ratio (%) 54 (23)* 75 (17)
*p < 0.001 vs. smokers and never-smokers.
Table 1: Demographic data of the study population and the results of lung function tests.
All
n (%)
R cases
(n = 574)
NR cases
(n = 431)
S cases
(n = 334)
Men (%) 48 52 44 49
Smoking status
Smokers, no. (%) 737 (55) 423 (74) 177 (41) 137 (41)
Never-smokers no. (%) 602 (45) 151 (26) 254 (59) 197 (59)
Respiratory symptoms 
at inclusion, no. (%)
839 (63) 574 166 (38) 99 (30)
Deaths, no. (%) 315 (24) 212 (37) 79 (18) 24 (7)
Lung transplant (no.) 56 51 3 2
Liver transplant (no.) 2 - 2 -
Mean (range) age at 
diagnosis (years)
41 (0-88) 51 (0.1-88) 40 (0.01-84) 24 (0-77)
Mean (range) age at 
inclusion (years)
47 (18-89) 54 (18-89) 45 (18-87) 35 (18-78)
Mean (range) follow-
up time (years)
9 (0.02-17) 8 (0.02-17) 10 (0.02-17) 11 (0.07-17)
Mean age (range) at 
death
67 (20-95) 67 (30-95) 69 (20-90) 61 (37-85)
Mean (SD) FEV1 (% 
predicted)
72 (33) 50 (29)* 88 (25) 89 (23)
Mean (SD) FVC (% 
predicted)
84 (23) 75 (25)* 89 (18) 93 (16)
Mean (SD) FEV1/FVC 
ratio (%)
63 (23) 48 (22)* 75 (17) 76 (15)
R: respiratory. NR: non-respiratory. S: screened.
*p < 0.001 vs. NR cases and S cases.Tanash et al. Respiratory Research 2010, 11:44
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14 years, which was estimated by the Kaplan-Meier
method. When the Kaplan-Meier analysis was stratified
by mode of identification, there was a significant differ-
ence in survival time between R cases, NR cases and S
cases, with estimated median survival times of 12 years,
14 years and 16 years, respectively, (p < 0.001), Figure 1.
The Kaplan-Meier analysis was also stratified by smoking
habits, Figure 2. The estimated median survival time for
the smokers was significantly lower than the never-smok-
ers, 13 and 14 years, respectively, (p < 0.01).
The SMR for the whole study population was 3.80 (95%
CI 1.80-2.30). Gender-specific SMRs were 3.80 (95%CI
3.20-4.40) for men and 3.90 (95% CI 3.30-4.60) for
women.
The smokers had a higher mortality risk than never-
smokers, with a SMR of 4.80 (95%CI 4.20-5.50) for the
smokers and 2.80 (95%CI 2.30-3.40) for the never-smok-
ers. The Rate Ratio (RR) was 1.70 (95% CI 1.35-2.20).
Stratifying the SMR by the mode of identification,
showed that the SMR was 4.70 (95% CI 4.10-5.40) for the
R cases and 3.0 (95%CI 2.35-3.70) for the NR cases. It
should be noted that the SMR for the S cases was also sig-
nificantly over 1, with 23 deaths and 9.9 expected (SMR
2.30 (95% CI 1.46-3.46)).
To assess the impact of bias by an interaction between
the smoking habits and mode of identification, the SMR
was calculated for the smokers and never-smokers in the
R, NR and S cases, Table 3. Among the R cases, the smok-
ers had a significantly higher mortality risk than the
never-smokers. The RR was 1.80 (95% CI 1.30-2.50). Also
for the S cases, the mortality risk of smokers was signifi-
cantly higher than the general Swedish population.
In the multivariate Cox model of mortality, including
1309 individuals with complete data on all predictors, i.e.
age over 50 years, FEV1% of predicted below 80% and the
presence of respiratory symptoms at inclusion, were sig-
nificantly associated with shorter survival time, Table 4.
Causes of death
Medical records were available for 302 (96%) decedents.
Autopsies were performed in 55 cases (18%). Autopsy
protocols were available for all of these cases. The main
causes of death were respiratory diseases in 175 (58%),
liver diseases in 37 (12%) and other diseases in 90 (30%),
Table 5. The 29 malignancy complications included 6 pul-
monary carcinoma, 8 urinary-genital carcinoma, 6 gas-
trointestinal malignancy, 3 melanoma, 2 lymphoma, 2
pancreas carcinoma and 2 breast carcinoma.
Discussion
In this study, the survival is presented for a large number
of adult PiZZ individuals who have been followed up pro-
spectively. The results confirm that PiZZ smokers, irre-
spective of mode of identification, have a significantly
higher mortality risk than the general Swedish popula-
tion. Our results show the importance of early detection
of AAT deficiency. All individuals with severe AAT defi-
ciency should be identified before they reach the age of
their smoking debut.
When the individuals were stratified by mode of identi-
fication, and the survival of smokers and never-smokers
was analysed, we found that even among the screened
cases, smokers had a reduced survival time compared
with never-smokers. However, also among the R cases
Figure 1 Kaplan-Meier analysis of mortality stratified by mode of 
identifiaction in 574 Respiratory cases, 431 Non-respiratory cas-
es, and 334 Screened cases. The analysis showed a significant differ-
ence in survival time between R cases, NR cases and S cases, with 
estimated median survival times of 12 years, 14 years and 16 years, re-
spectively (p < 0.001).
Figure 2 Kaplan-Meier analysis of mortality stratified by smoking 
habits in 737 smokers and 602 never-smokers. The analysis 
showed a significant difference in survival time between the smokers 
and the never-smokers, with estimated median survival times of 13 
years and 14 years, respectively, (p < 0.01).Tanash et al. Respiratory Research 2010, 11:44
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smokers had a significantly higher mortality risk than
never-smokers, with a SMR of 5.70 and 3.10, respectively.
Our results suggest also that increased mortality was
independently associated with higher age, lower FEV1
and the presence of respiratory symptoms at inclusion,
Table 4.
The current study extends previous studies regarding
mortality in PiZZ individuals by comparing the survival
of a large number of PiZZ individuals [2,13-17]. The three
groups R cases, NR cases and S cases differed with
respect to smoking habits, age at inclusion and lung func-
tion (Table 1). The NR cases and the S cases seem to have
normal lung function, but at the time of inclusion 38% of
the NR cases and 30% of the S cases had respiratory
symptoms, because in many cases the diagnosis was
made a long time before their inclusion in the registry.
Previous studies on the natural history of AATD have
been strongly influenced by ascertainment bias due to the
fact that AA T analysis is most often performed in sub-
jects with respiratory symptoms [13]. Therefore, many
Table 3: Standardised mortality ratios of smokers and never-smokers stratified by mode of identification.
Smokers Never-smokers
O/E SMR (95% CI) O/E SMR (95% CI) RR (95% CI)
Respiratory cases 156/27.20 5.70 (4.90-6.70) 57/18.20 3.10 (2.37-4.06) 1.80(1.30-2.50)
Non-respiratory 
cases
35/11.20 3.10 (2.20-4.34) 44/15.40 2.85 (2.07-3.83) 1.10(0.70-1.70)
Screened cases 17/5 3.40 (1.98-5.43) 6/5 1.20 (0.44-2.63) 2.80(1.10-10.40)
O: Observed number of deaths.
E: Expected number of deaths from the general population.
CI: Confidence interval.
RR: Rate ratio.
Table 4: Multivariable Cox Regression Models for Survival in PiZZ Individuals*
No. Risk Ratio 95%CI P value
Gender 0.90
Male 635 1.00 0.80-1.30 0.90
Female 674 1.0
Age at inclusion, years <0.001
>50 580 5.50 4.0-7.50 <0.001
≤50 729 1.0
Pre-bronchodilator 
FEV1 % of predicted
<0.001
183 4.30 2.90-6.40 <0.001
< 30 230 2.00 <0.001
30-49 263 1.60 1.40-3.00 0.020
50-79 633 1.0
≥ 80 1.10-2.40
Respiratory symptoms 
at inclusion&
0.001
Yes 820 2.20 1.40-3.50 0.001
No 489 1.0
** 1309 individuals with complete data on included predictors.
&irrespective of mode of identification.Tanash et al. Respiratory Research 2010, 11:44
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asymptomatic PiZZ individuals escape detection. The
earliest study on the natural history of AATD, published
by Larsson, indicated that it is a serious disorder associ-
ated with a poor prognosis [2]. He determined the cumu-
lative probability of survival in 248 PiZZ subjects and
found it to be significantly reduced compared with the
normal Swedish population. In his study the median sur-
vival time was only about 40 years for smokers, and 65
years for never-smokers. However, the study population
was highly selected. Ninety percent of the patients were
identified because of symptoms and the majority were
smokers. Another study of 124 AAT-deficient patients
published by Brantly showed the cumulative probability
of survival to age 50 of 52% and only a 16% chance of sur-
viving to 60 years of age [14]. The majority of the individ-
uals in this study were men, ex-smokers who had become
dyspnoeic between 25 and 40 years of age. Because of the
selection bias in both of these studies, the estimated life
expectancy was probably too pessimistic. Recently, some
studies have reported long-term survival and causes of
death [15-17]. Seersholm analysed the life expectancy of
255 non-index patients who did not have pulmonary
symptoms [15]. As in the current study, the survival of
smokers in non-index cases was less than that of never-
smokers and never-smokers did not have an excess mor-
tality compared with the normal Danish population.
However, this study did not show any difference in sur-
vival between smokers and never-smokers in index cases.
The study included only a limited number of never-
smokers and used a different approach for the survival
calculation. In another study, Seersholm reported that
FEV1 was a major risk factor for mortality in patients with
severe AAT deficiency, stating that the median survival
time for patients with FEV1 below 25% of predicted was
only 6.3 years [16]. A mortality study recently published
by Stoller et al. showed that severe airflow obstruction
was a major determinant of mortality. Increasing age,
lower FEV1 and lower education level were also associ-
ated with higher mortality [17]. The most common
underlying causes of death were emphysema (72%) and
liver cirrhosis (10%). This study compared the clinical
features between decedents and survivors in the U.S. reg-
istry, but no comparisons between smokers and never-
smokers were made. Neither respiratory nor other symp-
toms were reported, nor was the mode of identification.
The SMR was stratified by quintiles of initial postbron-
Table 5: The main causes of death in 302 decedents.
All
N = 302
n (%)
Smoker
N = 197
n (%)
Never-smokers
N = 105
n (%)
Respiratory 175 (58) 134 (68) 41 (39)
Respiratory failure 117 92 25
Pneumonia 48 34 14
Pneumothorax 10 8 2
Hepatic 37 (12) 15 (8) 22 (21)
Liver failure 13 7 6
Primary liver carcinoma 18 7 11
Gastrointestinal bleeding 4 - 4
Intra-abdominal infection 2 1 1
Other 90 (30) 48 (24) 42 (40)
Malignancy complication 29 14 15
Cardiovascular accident 23 14 9
Cerebrovascular accident 14 6 8
Intra-abdominal 
infection*
862
Gastrointestinal 
bleeding*
211
Pulmonary embolism 6 4 2
Suicide/accident 5 3 2
Renal failure 3 - 3
* without known liver diseaseTanash et al. Respiratory Research 2010, 11:44
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chodilator FEV1, not by smoking habits or mode of iden-
tification, In contrast to our study, primary liver
carcinoma was not found as a cause of death in the study
by Stoller et al.
The natural history of AATD is incompletely known,
although more than 40 years have elapsed since the defi-
ciency was discovered. The selection in the Swedish
national AAT registry is less skewed than in other regis-
tries in which most of the patients are identified because
of respiratory symptoms. In the Swedish AAT registry,
the majority of subjects is identified by reasons other
than respiratory symptoms, and includes a large number
of never-smokers. However, only 25% of the individuals
were identified by family/population screening, and the
remainder was identified by a disease or symptoms. Fur-
thermore, although the detection rate of AATD is rela-
tively high (20%) in Sweden, the majority of adult PiZZ
individuals remains unidentified, and their health status
is unknown, which is one limitation of our study. Another
limitation is that we reported lung function as pre-bron-
chodilator FEV1, because a reversibility test was not per-
formed in all cases. The third limitation is that we
compared the SMR for the study population with the
SMR for the general Swedish population, because no data
are available on mortality in the subgroups based on
smoking habits in the general Swedish population.
Conclusion
We conclude that PiZZ smokers, irrespective of mode of
identification, have a significantly higher mortality risk
than the general Swedish population. Early detection of
AAT deficiency is important in order to make it possible
to implement protective measures such as inhibiting
smoking.
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